Haematologica (May 2007)

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

  • Stefano Pulini,
  • Serena Rupoli,
  • Gaia Goteri,
  • Nicola Pimpinelli,
  • Renato Alterini,
  • Angela Tassetti,
  • Anna Rita Scortechini,
  • Massimo Offidani,
  • Simonetta Mulattieri,
  • Andrea Stronati,
  • Giuliano Brandozzi,
  • Alfredo Giacchetti,
  • Giorgio Mozzicafreddo,
  • Giuseppe Ricotti,
  • Giorgio Filosa,
  • Alberta Bettacchi,
  • Marco Simonacci,
  • Nicolino Novelli,
  • Pietro Leoni

DOI
https://doi.org/10.3324/haematol.10879
Journal volume & issue
Vol. 92, no. 5

Abstract

Read online

Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I–IIA and IIB–IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.